Clinical trials: Vaccine Prophylaxis
Hib Disease, Hepatitis B
Immune Memory Foll Pry Vaccination With DTPw-HBV/Hib Vaccine Formulation; Immuno & Reacto of Booster Dose at 15-18 Mths
To assess the anti-PRP antibody response one month after vaccination in the groups receiving a fourth consecutive dose of two formulations of DTPw-HBV/Hib vaccine
- Conditions
- Hib Disease, Hepatitis B, Pertussis, Prophylaxis of Diphtheria
- Trial name
- NCT00158808
- Testing
- Diphteria, tetanus, whole-cell pertussis, hepatitis B & Hib
- Where
- Philippines
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Zika Virus, Zika Virus Infection
Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy Adults
In this Phase 1 study, two target dose levels of VLA1601, a purified, inactivated, whole Zika virus (ZIKV) vaccine candidate adsorbed on aluminum hydroxide (alum) will be evaluated: 6 antigen units (AU) and 3 AU of inactivated…
- Trial name
- NCT03425149
- Testing
- VLA1601
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Healthy
Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
This study was aimed to explore safety and immunogenicity of two formulations of a Meningococcal B Vaccine when administered to healthy infants.
- Trial name
- NCT00381615
- Testing
- rMenB, rMenB+OMV, DTaP-Hib-IPV
- Where
- 3 sites in United Kingdom
- Volunteers
- 147 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Rabies Post-exposure Prophylaxis, Rabies
Real-World Effectiveness of Zamerovimab and Mazorelvimab and Vaccine for Rabies Grade III Exposure in Nanyang
The objective of this real-world, prospective observational study is to evaluate the clinical effectiveness of zamerovimab and mazorelvimab injection (a human rabies monoclonal antibody cocktail) administered in combination with…
- Trial name
- NCT07624461
- Testing
- Zamerovimab and Mazorelvimab Injection plus Rabies Vaccine
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Synermore Biologics (Suzhou) Co., Ltd.
Interpandemic Influenza
Safety and Immunogenicity of Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2008-2009
Trial for annual approval of interpandemic influenza vaccines
- Trial name
- NCT00734734
- Testing
- Seasonal Influenza Vaccine
- Where
- 2 sites in Italy
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Diarrhea
Safety and Immunogenicity Study of Traveler's Diarrhea Vaccine Patch
The purpose of this study is to evaluate and compare the safety and immune responses following a two vaccination regimen by transcutaneous immunization with heat-labile enterotoxin of E.
- Trial name
- NCT01067781
- Testing
- Heat-Labile Enterotoxin of E. coli (LT)
- Where
- 5 sites in United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Intercell USA, Inc.
Prevention of Influenza
Safety, Tolerability and Immunogenicity of an Trivalent Inactivated Cell-Culture Influenza Vaccine in Healthy Adults
A randomized, double-blinded, controlled, Phase I clinical trial to assess the safety, tolerability and immunogenicity of 'NBP607(trivalent inactivated cell-culture influenza vaccine)' compared to egg-based influenza vaccine in…
- Trial name
- NCT03893669
- Testing
- NBP607, Agrippal
- Where
- South Korea
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- SK Chemicals Co., Ltd.
COVID-19
A Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Adults Aged 18 Years and Older (COVID-19)
The study will be a multi-national, endpoint-driven, randomized, double-blind, placebo-controlled, adaptive study in which participating adults will be randomized 1:1 to receive 2 doses of either candidate vaccine or placebo on…
- Trial name
- NCT04852705
- Testing
- SARS-CoV-2 Vaccine (Vero Cells), Inactivated
- Volunteers
- 28,000 people, healthy volunteers welcome
- Sponsor
- Shenzhen Kangtai Biological Products Co., LTD
Prevention of TB Recurrence
Study to Check the Efficacy and Safety of Recombinant BCG Vaccine in Prevention of TB Recurrence
This is a Phase II/III trial with two groups of adults successfully cured of category 1 pulmonary TB receiving either VPM1002 or placebo.
- Trial name
- NCT03152903
- Testing
- VPM1002 (Recombinant BCG Vaccine)
- Where
- 10 sites in Bangladesh, India
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
COVID-19
Safety and Immunogenicity Study of Booster Vaccination in Different Doses of COVID-19 Vaccine (Vero Cell),Inactivated for Prevention of COVID-19
This is a randomized, double-blinded, phase Ⅳ clinical trial of COVID-19 vaccine (Vero cell), Inactivated manufactured by Sinovac Life Sciences Co. , Ltd.
- Trial name
- NCT05165966
- Testing
- High-dosage of COVID-19 vaccine (Vero cell), Inactivated, Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated
- Where
- China
- Volunteers
- 340 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Covid19
Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subjects
VXA-CoV2-1 is a non-replicating Ad5 vector adjuvanted oral tableted vaccine being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection.
- Trial name
- NCT04563702
- Testing
- VXA-CoV2-1
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Vaxart
Hepatitis B
Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients
The purpose of this study is to find out if a new investigational hepatitis B virus vaccine, HEPLISAV™, is safe in patients at least 40 years of age who have progressive loss of kidney function with more advanced stage 3 (GFR ≤…
- Trial name
- NCT00426712
- Testing
- 1018 ISS immunostimulatory oligonucleotide with HBV surface antigen, Hepatitis B Vaccine (Recombinant)
- Where
- 4 sites in United States
- Volunteers
- 42 people
- Sponsor
- Dynavax Technologies Corporation
Meningococcal Disease
Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Same Vaccine
The proposed study V72P6E1 is an Extension Study of V72P6 (NCT00381615). The objectives of this extension study will be to explore antibody persistence at approximately 40 months of age and to evaluate the safety, tolerability…
- Trial name
- NCT01027351
- Testing
- Meningococcal (group B) multicomponent recombinant adsorbed vaccine., Meningococcal (group B) multicomponent recombinant adsorbed vaccine, without Outer Membrane Vesicles (OMV)
- Where
- United Kingdom
- Volunteers
- 163 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Prevention of Anthrax Infection
Trial to Evaluate the Safety and Immunogenicity of an Anthrax Recombinant Protective Antigen Vaccine
The purpose of this phase 1 study is to evaluate the safety and immunogenicity of rPA102 vaccine, using anthrax vaccine adsorbed (AVA) as a comparator.
- Trial name
- NCT00103467
- Testing
- rPA102 Vaccine
- Where
- 4 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- VaxGen
Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants
The study will evaluate the efficacy of Ad26.COV2.S in the prevention of molecularly confirmed moderate to severe/critical COVID-19, as compared to placebo, in adult participants.
- Trial name
- ENSEMBLE (NCT04505722)
- Testing
- Ad26.COV2.S
- Where
- 225 sites in United States, Argentina and 6 more
- Volunteers
- 44,325 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Influenza Prophylaxis
Tolerability and Immunogenicity Study of Fluval AB Suspension for Injection
To assess immunogenicity of a single intramuscular injection of Fluval AB suspension for injection (trivalent, seasonal influenza vaccine, active ingredient content: 15 μgHA/0.5mL of seasonal A/H1N1, A/H3N2 and B influenza…
- Trial name
- NCT01863849
- Testing
- Vaccination with Fluval AB suspension for injection
- Where
- 3 sites in Hungary
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Fluart Innovative Vaccine Ltd, Hungary
Pneumococcal Infections
Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
This study will assess the safety, tolerability and immune response of 13-valent pneumococcal conjugate vaccine (13vPnC) compared with 23-valent Pneumococcal Polysaccharide Vaccine (23vPS).
- Trial name
- NCT00427895
- Testing
- 13-valent pneumococcal conjugate vaccine (13vPnC), 23-valent Pneumococcal Polysaccharide Vaccine (23vPS)
- Where
- 26 sites in United States
- Volunteers
- 2,141 people, healthy volunteers welcome
- Sponsor
- Pfizer
Mumps, Rubella
Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
This is a study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals live attenuated measles-mumps-rubella-varicella vaccine given to healthy children in their second year of life.
- Conditions
- Mumps, Rubella, Measles, Varicella
- Trial name
- NCT00126997
- Testing
- Measles, Mumps, Rubella and Chickenpox (live vaccine)
- Where
- 54 sites in Finland, Germany and 2 more
- Volunteers
- 1,439 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease (COPD)
Evaluation of the Efficacy and Safety of MV130 in Chronic Obstructive Pulmonary Disease (COPD)
The goal of this clinical trial is to learn whether the bacterial vaccine MV130 helps reduce the number of exacerbations in adults with moderate to severe COPD. It will also assess the safety and immune effects of MV130.
- Trial name
- MV130 (NCT01842360)
- Testing
- MV130
- Where
- 7 sites in Spain
- Volunteers
- 198 people
- Sponsor
- Inmunotek S.L.
Vaccine, Crimean-Congo Hemorrhagic Fever
Safety and Immunogenicity of a Self-Amplifying RNA Vaccine Against Crimean-Congo Hemorrhagic Fever
The goal of this clinical trial is to assess the safety, tolerability and immunogenicity of three dosage levels, and a single or two-dose administration regimen, of the investigational HDT-321 product administered…
- Trial name
- NCT06799013
- Testing
- 10 ug HDT 321, 25ug HDT-321, 50ug HDT-321
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- HDT Bio